New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
05:56 EDTCBLICleveland BioLabs downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Cleveland BioLabs calling BARDA's decision to terminate negotiations for the continued development of Entolimod a significant setback.
News For CBLI From The Last 14 Days
Check below for free stories on CBLI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
07:10 EDTCBLICleveland BioLabs announces approval to start CBLB612 Phase 1 study in Russia
Subscribe for More Information
September 10, 2014
07:37 EDTCBLICleveland BioLabs announces extra 180 days to regain NASDAQ compliance
Subscribe for More Information
September 8, 2014
07:06 EDTCBLICleveland BioLabs, Sabby announce resolution of litigation
Subscribe for More Information
September 3, 2014
14:09 EDTCBLICleveland BioLabs up 41% in afternoon trading following FDA opinion on entolimod
Subscribe for More Information
07:23 EDTCBLICleveland BioLabs to host conference call
Conference call to discuss update of July FDA meeting will be held on September 3 at 11 am. Webcast Link
07:06 EDTCBLICleveland BioLabs to submit pre-EUA application for entolimod
Cleveland BioLabs announced that the minutes from its meeting with the FDA in July confirmed that the company's existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization, or pre-EUA, submission for entolimod for reducing the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster. The FDA has granted Fast Track status to entolimod and Orphan Drug status for prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use